Related Experiment Video
Updated: Nov 5, 2025

08:35
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
8.1K
Targeting Bcl-2 for cancer therapy.
Linlin Zhang1, Zaiming Lu1, Xiangxuan Zhao1
1Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 110004, LN, China.
Biochimica Et Biophysica Acta. Reviews on Cancer
|May 20, 2021
Summary
Targeting the Bcl-2 family of proteins, which regulate apoptosis, offers a promising strategy for cancer treatment by enhancing cancer cell death and overcoming resistance to therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Apoptosis deficiency is a hallmark of neoplastic diseases.
- The Bcl-2 protein family are key regulators of apoptosis.
- Bcl-2 hyperactivation is linked to cancer progression and therapeutic resistance.
Purpose of the Study:
- To review the roles of Bcl-2 in cancer.
- To discuss the clinical potential of targeting Bcl-2.
Main Methods:
- Literature review of research and clinical studies on Bcl-2 family proteins in cancer.
Main Results:
- Bcl-2 family proteins significantly influence cancer occurrence, progression, and prognosis.
- Targeting Bcl-2 inactivation enhances apoptotic sensitivity and reverses drug resistance.
Conclusions:
- Targeting Bcl-2 represents a promising therapeutic strategy for cancer treatment.
- Further exploration of Bcl-2's clinical value in cancer therapeutics is warranted.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K
Combination Therapies and Personalized Medicine
5.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.4K
The Intrinsic Apoptotic Pathway
7.2K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
7.2K
Tumor Immunotherapy
798
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
798
Inhibition of Cdk Activity
5.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K

